India's pharmaceutical industry faces critical supply chain vulnerabilities that demand immediate action. The country's $60 billion pharma sector must reduce its heavy reliance on imported raw materials and active pharmaceutical ingredients to strengthen resilience against global disruptions. While complete import substitution may be unrealistic, the government is pushing for maximum localization efforts. Simultaneously, Indian companies need to identify and expand into markets with stronger export potential to protect growth. Recent data shows India's pharma exports reached $28.29 billion from April 2025 to February 2026, marking 5.6 percent growth, though geopolitical tensions in West Asia have created shipment challenges. The industry must balance domestic pharmaceutical needs while advancing in emerging segments like biosimilars to maintain its competitive edge globally.
